Glenmark Nitroglycerin sublingual tablets recalled for manufacturing deviations
Glenmark Pharmaceuticals is recalling specific lots of Nitroglycerin sublingual tablets 0.4 MG nationwide due to manufacturing process deviations.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: Class II voluntary recall initiated by the firm based on manufacturing process deviations. The classification and voluntary nature indicate a precautionary measure.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is recalling specific lots of Nitroglycerin sublingual tablets 0.4 MG due to manufacturing process deviations. The affected product was distributed nationwide in the United States.
The recall includes three specific lots: lot 17232024 (expiring August 2025), lot 17232071 (expiring September 2025), and lot 17232072 (expiring September 2025). The firm initiated the voluntary recall on March 13, 2025, and the FDA classified it as a Class II recall on April 8, 2025.
Patients taking affected lots should contact their healthcare provider about their medication. Healthcare providers and patients can reference the FDA recall notice with recall number D-0324-2025 for complete product details and lot information.
The recalled product
- Product
- NITROGLYCERIN (NITROGLYCERIN)
- Brand
- NITROGLYCERIN
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug — Cardiovascular
- Hazard
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot # 17232024
- exp. date Aug-25 17232071
- exp. date Sep-25 17232072
- exp. date Sep-25
UPCs (3)
- 0368462638019
- 0368462639016
- 0368462640012
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · NITROGLYCERIN
- ModerateNitroglycerin Sublingual Tablets Recalled for Manufacturing Practice Deviations
FDA (Drugs) · 2025-04-16
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27